Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trialEnriqueta Felip, Heather A. Wakelee, Nasser K. Altorki et al.|The Lancet|2021Cited by 1.5k
Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trialMartin Reck, Denis Moro‐Sibilot, Christian A. Thomas et al.|The Lancet Respiratory Medicine|2019Cited by 937
Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133)Stephen V. Liu, Leora Horn, Martin Reck et al.|Journal of Clinical Oncology|2021Cited by 818
Estradiol/GPER affects the integrity of mammary duct-like structures in vitroYu Deng, Akira Nakanishi|Scientific Reports|2020Cited by 27
Protective role of mRNA demethylase FTO on axon guiding molecules of nigro-striatal projection system in manganese-induced ParkinsonismZhipeng Qi, Yu Deng|Research Square|2021Cited by 0